Big Pharma and Big Medicine have faced many huge challenges over the past years to keep their cash cows—people with type-2 diabetes—each forking over an average of $13,700 annually (approximately 2.3 times more than what expenditures would be in the absence of diabetes). This financially rewarding system works well until the blood-sugar-lowering medicines, along with the gadgets and tests they rely on, are proven to be useless and dangerous. Unfortunately for the patients, industry fights back, defending their treasure-trove by hiring pricey medical experts, factoring in expected lawsuits, and exaggerating the benefits and minimizing the harms of their products.
